Navigation Links
China-Biotics, Inc. Receives Manufacturing Certificate for New Products
Date:1/20/2009

SHANGHAI, China, Jan. 20 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (Nasdaq: CHBT) ("China-Biotics," "the Company"), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced the State Food and Drug Administration has approved manufacturing certificates for the production of several new products, including Synbiotics Capsules, Probiotics Gegen Capsules, Probiotics Tremella Polysaccharide Capsules and Probiotics Chewable Tablets.

"These new certificates will enable us to successfully expand our product portfolio," said Mr. Jinan Song, China-Biotics' Chairman and Chief Executive Officer. "The launch of the new products will better serve our existing customers and support our continuing regional retail expansion."

The new probiotics-based products were developed during an eight-month process and are currently in production at the Company's existing manufacturing facility.

The products are intended to offer several different health solutions to consumers. Synbiotics Capsules' primary active ingredients are lactobacillus thermophilus, infant bifidobacterium, bifidobacterium bifidum and oligo- fructose, which can enhance adolescents' immune systems and gastrointestinal ("GI") health. Probiotics Gegen Capsules' primary active ingredients are lactobacillus acidophilus and bifidobacterium bifidum ("LA-BB") and gegen powder, a traditional Chinese medicinal herb, which can enhance women's GI health and relieve menopausal symptoms. Probiotics Tremella Polysaccharide Capsules' primary active ingredients are LA-BB and tremella polysaccharide, which can enhance the GI health and immune systems of seniors. Probiotics Chewable Tablets' primary active ingredients are lactobacillus acidophilus, infant bifidobacterium and t
'/>"/>

SOURCE China-Biotics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
2. China-Biotics, Inc. Launches Shining Probiotics Protein Powder
3. China-Biotics, Inc. Receives Approval to Begin Construction on Large-Scale Manufacturing Facility
4. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter FY 2008 Results
5. China-Biotics, Inc. Launches English / Chinese Corporate and Investor Relations Web Site
6. China-Biotics, Inc. Announces Rescheduling of Conference Call to Discuss Third Quarter 2008 Results
7. China-Biotics, Inc. Reports Third Quarter 2008 Financial Results
8. China-Biotics, Inc. Completes Foundation for Its New Plant
9. China-Biotics, Inc. to Present at Two Upcoming Investor Conferences
10. China-Biotics, Inc. to Supply Probiotics to Pharmaceutical Company
11. China-Biotics, Inc. Announces Conference Call to Discuss Fourth Quarter and Full Year 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Vivakor Confirms Record Date of Stock Dividend 2Vivakor Confirms Record Date of Stock Dividend 3Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2